In contrast, Navitoclax and Venetoclax only partially reduced neutrophil survival at the highest dose (100 nM) (Fig. EV3B), showing that Bcl-xL but not Bcl-2 mediates neutrophil survival in tumor supernatant conditions. The gene discussed is BCL2; the disease is neoplasm.